{"id":810165,"date":"2025-02-06T16:33:45","date_gmt":"2025-02-06T21:33:45","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\/"},"modified":"2025-02-06T16:33:45","modified_gmt":"2025-02-06T21:33:45","slug":"fulcrum-therapeutics-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-sciences-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\/","title":{"rendered":"Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">CAMBRIDGE, Mass., Feb.  06, 2025  (GLOBE NEWSWIRE) &#8212; Fulcrum Therapeutics, Inc.<sup>\u00ae<\/sup> (the \u201cCompany\u201d) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025 at 1:20 pm ET.<\/p>\n<p>The webcast of the fireside chat will be accessible <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=dukZuY9iaFcXgptIGzxcB9dvtsfLXxiAraIJiuyiDRXY3v3m8reaOTVJdC_Y21nXfV1BxXE6wELULwEbMy26KPGGQ3uc2CMgvhzfk3MG54pmDEJdeM9rVgGEadCCLzxv6y4k_y9OeuyLhWyhDxT-7FInwM5mwTa-OwSBWACd09udrcFQkYA2UMnLLZ0i0A7gaDUWDwjcwUVELGh6tSgbxnoTETT3zfV72CfC8RpovKNh9o76afyno3xSjNzku5nQF32MIsCYxUTswY8h8Ack_CsgJ1K_Cy3PaUAT-6lgxw48sNksAXf48kbL81O1RBlnWD80FEULmH-yC7W4Uboibep3HH81xDCCs1BYC6-NovN7N0QjU81_X2durUAuxgAbOdp6xYkvUCQak6IEDjRVMo0CJhiY0g-l5n8JlPZ9-7QgcTrQDEXVDqtNa0WDTnXoiyxAHG9MzuxRwcKYKgoNa_PlGTuva3CPoUMbw9Cz0zpgYHKKVXfz5kDtOnxVHilvysv7sQZanoX30-SLEqi8iV0Cv99SB0IMCzbs9-2Hb9iSJ96i8n3eNRliAnSFC7fo_OLjzlbiz608YpQkvnyrq_BV0J-R8PLUb-YZ5HyWcFGw6eyKShImBrzXP0snhnGlZ9V8Q3YaDBJBK_6CoXLz1Q==\" rel=\"nofollow\" target=\"_blank\">HERE<\/a> and by visiting the &#8220;Events and Presentations&#8221; section of Fulcrum Therapeutics\u2019 website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Oz8RANRVeZid97Orbg9Eh52FzVaNhM0eaAwqeOoTgfamcI7c9swU94w16CNbtderPLLrDPR4UnmMXHAxNVrDrfq14_9kddCs71c7liYwvjldWgfy00mKpE_ddUoj-Ue-ddlUeHwHy5FFyhOTI-FP-j_ZGvGbltzsJib71zTMx0oDMeLl3Nqo29wlW9a_7Divg3chKsfQmg3f37TzcsFbG8nNQtLd0GGEfIU0aDDsrtC787toed8DEfvIZc-6yPV9yS4BTZDpMnDyB9tsBs6pRUOsuuEn3f01Ik5vypou5NEJLVfaG1Nefh-kYV8EuUrETrkPEbM_Em-xIwRCR0lYK_2RFLlnmu6m0giygV-eFRpArcAvl1kL97peghYmhMPd\" rel=\"nofollow\" target=\"_blank\"><strong>https:\/\/ir.fulcrumtx.com\/events-and-presentations<\/strong><\/a>. A replay of the webcast will be available on Fulcrum Therapeutics\u2019 website for at least 30 days following the presentation.<\/p>\n<p>\n        <strong>About Fulcrum Therapeutics<\/strong><br \/>\n        <br \/>Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum\u2019s lead program in clinical development is pociredir, a small molecule designed to increase expression of fetal hemoglobin and in development for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter\/X (@FulcrumTx) and LinkedIn.<\/p>\n<p>\n        <strong>Contact:<\/strong><br \/>\n        <br \/>Chris Calabrese<br \/>LifeSci Advisors, LLC<br \/>ccalabrese@lifesciadvisors.com<\/p>\n<p>Kevin Gardner<br \/>LifeSci Advisors, LLC<br \/>kgardner@lifesciadvisors.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NDM5NiM2NzM5NjkwIzIxODM1NDI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MDhjMjY1ZjctOTg5My00NmRlLWE1ZjItNTNiYjkwNzJhNTcyLTExOTUxMDA=\/tiny\/Fulcrum-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) &#8212; Fulcrum Therapeutics, Inc.\u00ae (the \u201cCompany\u201d) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025 at 1:20 pm ET. The webcast of the fireside chat will be accessible HERE and by visiting the &#8220;Events and Presentations&#8221; section of Fulcrum Therapeutics\u2019 website at\u00a0https:\/\/ir.fulcrumtx.com\/events-and-presentations. A replay of the webcast will be available on Fulcrum Therapeutics\u2019 website for at least 30 days following the presentation. About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-810165","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) &#8212; Fulcrum Therapeutics, Inc.\u00ae (the \u201cCompany\u201d) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025 at 1:20 pm ET. The webcast of the fireside chat will be accessible HERE and by visiting the &#8220;Events and Presentations&#8221; section of Fulcrum Therapeutics\u2019 website at\u00a0https:\/\/ir.fulcrumtx.com\/events-and-presentations. A replay of the webcast will be available on Fulcrum Therapeutics\u2019 website for at least 30 days following the presentation. About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small &hellip; Continue reading &quot;Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-06T21:33:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NDM5NiM2NzM5NjkwIzIxODM1NDI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fulcrum-therapeutics-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fulcrum-therapeutics-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference\",\"datePublished\":\"2025-02-06T21:33:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fulcrum-therapeutics-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\\\/\"},\"wordCount\":232,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fulcrum-therapeutics-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NDM5NiM2NzM5NjkwIzIxODM1NDI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fulcrum-therapeutics-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fulcrum-therapeutics-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\\\/\",\"name\":\"Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fulcrum-therapeutics-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fulcrum-therapeutics-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NDM5NiM2NzM5NjkwIzIxODM1NDI=\",\"datePublished\":\"2025-02-06T21:33:45+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fulcrum-therapeutics-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fulcrum-therapeutics-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fulcrum-therapeutics-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NDM5NiM2NzM5NjkwIzIxODM1NDI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NDM5NiM2NzM5NjkwIzIxODM1NDI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fulcrum-therapeutics-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\/","og_locale":"en_US","og_type":"article","og_title":"Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Market Newsdesk","og_description":"CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) &#8212; Fulcrum Therapeutics, Inc.\u00ae (the \u201cCompany\u201d) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025 at 1:20 pm ET. The webcast of the fireside chat will be accessible HERE and by visiting the &#8220;Events and Presentations&#8221; section of Fulcrum Therapeutics\u2019 website at\u00a0https:\/\/ir.fulcrumtx.com\/events-and-presentations. A replay of the webcast will be available on Fulcrum Therapeutics\u2019 website for at least 30 days following the presentation. About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small &hellip; Continue reading \"Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-06T21:33:45+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NDM5NiM2NzM5NjkwIzIxODM1NDI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference","datePublished":"2025-02-06T21:33:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\/"},"wordCount":232,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NDM5NiM2NzM5NjkwIzIxODM1NDI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\/","name":"Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NDM5NiM2NzM5NjkwIzIxODM1NDI=","datePublished":"2025-02-06T21:33:45+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NDM5NiM2NzM5NjkwIzIxODM1NDI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NDM5NiM2NzM5NjkwIzIxODM1NDI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/810165","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=810165"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/810165\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=810165"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=810165"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=810165"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}